Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Market Cap | Price | Price Target | Upside/Downside | Top Analysts Upside/Downside | Consensus | Top Analysts Consensus | Analysts | Top Analysts | Fore. Revenue Growth | Fore. Earnings Growth | Forecast ROE | Forecast ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SLNO | SOLENO THERAPEUTICS INC | $2.04B | $39.49 | $90.00 | 127.91% | Strong Buy | 5 | 97.53% | 324.84% | 119.61% | 95.49% | |||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $42.29B | $318.85 | $459.94 | 44.25% | Strong Buy | 18 | 34.31% | 83.15% | 348.08% | 55.31% | |||
| ADMA | ADMA BIOLOGICS INC | $2.19B | $9.19 | N/A | N/A | N/A | N/A | 23.40% | 36.37% | 109.42% | 83.67% | |||
| ZVRA | ZEVRA THERAPEUTICS INC | $551.89M | $9.40 | $23.67 | 151.78% | Strong Buy | 3 | 42.94% | 24.36% | 125.56% | 68.20% | |||
| CORT | CORCEPT THERAPEUTICS INC | $4.52B | $42.49 | $88.33 | 107.89% | Buy | 3 | 25.94% | 64.76% | 102.67% | 79.50% | |||
| ABEO | ABEONA THERAPEUTICS INC | $274.98M | $4.82 | $20.00 | 314.94% | Buy | 1 | 250.75% | 24.03% | 92.83% | 67.31% | |||
| HALO | HALOZYME THERAPEUTICS INC | $7.61B | $64.49 | $78.56 | 21.81% | Buy | 9 | 16.28% | 60.08% | 2,350.14% | 45.43% | |||
| KRYS | KRYSTAL BIOTECH INC | $7.63B | $260.95 | $326.25 | 25.02% | Strong Buy | 8 | 35.15% | 28.36% | 62.02% | 56.71% | |||
| RPRX | ROYALTY PHARMA PLC | $28.02B | $48.57 | $49.67 | 2.26% | Strong Buy | 3 | 16.02% | 50.65% | 42.64% | 21.11% | |||
| VCEL | VERICEL CORP | $1.73B | $34.14 | $54.50 | 59.64% | Strong Buy | 2 | 17.77% | 56.51% | 22.34% | 16.23% | |||
| NAGE | NIAGEN BIOSCIENCE INC | $350.75M | $4.38 | $13.00 | 196.80% | Strong Buy | 1 | 17.44% | 45.24% | 67.24% | 48.36% | |||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $1.60B | $27.74 | $44.00 | 58.62% | Buy | 6 | 14.72% | 22.30% | 21.79% | 14.91% | |||
| TECH | BIO-TECHNE CORP | $8.31B | $53.13 | $73.71 | 38.74% | Strong Buy | 7 | 6.03% | 69.71% | 21.86% | 17.43% | |||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $10.67B | $55.50 | $87.88 | 58.33% | Strong Buy | 16 | 12.23% | 56.61% | 28.65% | 22.97% | |||
| APLS | APELLIS PHARMACEUTICALS INC | $5.17B | $40.41 | $35.53 | -12.07% | Buy | 15 | 6.37% | 63.56% | 57.54% | 19.81% | |||
| MNKD | MANNKIND CORP | $770.25M | $2.50 | $7.10 | 184.00% | Buy | 5 | 15.77% | 140.36% | -158.09% | 10.18% | |||
| EXEL | EXELIXIS INC | $11.40B | $43.88 | $43.80 | -0.18% | Hold | 10 | 12.77% | 18.63% | 64.86% | 49.28% | |||
| CPRX | CATALYST PHARMACEUTICALS INC | $3.02B | $24.69 | $35.00 | 41.76% | Strong Buy | 1 | 9.45% | 6.96% | 60.44% | 52.24% | |||
| REGN | REGENERON PHARMACEUTICALS INC | $80.54B | $761.85 | $832.21 | 9.24% | Buy | 19 | 10.39% | 13.03% | 23.23% | 17.90% | |||
| VCYT | VERACYTE INC | $2.56B | $32.25 | $44.33 | 37.47% | Buy | 6 | 12.19% | 24.92% | 12.54% | 11.68% | |||
| LGND | LIGAND PHARMACEUTICALS INC | $3.98B | $199.59 | $245.86 | 23.18% | Strong Buy | 7 | 11.02% | 18.52% | 22.50% | 14.66% | |||
| VRTX | VERTEX PHARMACEUTICALS INC | $111.45B | $438.71 | $546.00 | 24.46% | Strong Buy | 21 | 10.95% | 16.80% | 39.80% | 28.97% | |||
| UTHR | UNITED THERAPEUTICS CORP | $24.75B | $564.81 | $614.33 | 8.77% | Buy | 9 | 11.96% | 6.98% | 26.79% | 24.13% | |||
| XOMA | XOMA ROYALTY CORP | $392.65M | $32.98 | $67.00 | 103.15% | Strong Buy | 4 | 14.75% | 11.38% | N/A | N/A | |||
| INCY | INCYTE CORP | $19.09B | $95.93 | $107.75 | 12.32% | Buy | 16 | 8.55% | 13.91% | 15.10% | 11.21% | |||
| CRMD | CORMEDIX INC | $557.31M | $7.05 | $13.50 | 91.49% | Strong Buy | 4 | 4.44% | 0.16% | 37.60% | 18.45% | |||
| MDXG | MIMEDX GROUP INC | $582.38M | $3.92 | $9.50 | 142.35% | Strong Buy | 4 | 1.87% | 0.61% | 21.26% | 15.92% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.